Peptide science at the intersection of diet, metabolism, and performance.

Peptidegenics

An independent reference on how peptides interact with diet, metabolism, body composition, and training. No supplements sold. No affiliates. No agenda.

Browse by Metabolic Context

All contexts →
Caloric Deficit & Fat Loss

How peptides affect fat oxidation, muscle retention, and metabolic rate during energy restriction.
Anabolic Environment & Muscle

Growth hormone axis peptides, mTOR, protein synthesis, and what training stimulus has to do with it.
Fasting & Metabolic Switching

Peptide interactions with fasting windows, ketosis, autophagy, and insulin signalling.
Performance & Recovery Nutrition

Pre- and post-training peptide timing, recovery nutrition context, and substrate utilisation.

Latest Articles

View all →
Metabolic Oncology Extrapolated

How Do Semaglutide's 2026 Oncogenic and Cardiotoxicity Numbers Recalibrate the Risk-Benefit Equation for Body-Composition Practitioners?

A 2026 narrative review in Pharmaceuticals (MDPI) and ASCO 2026 real-world data reframe semaglutide's oncogenic and cardiotoxicity profile in quantitative terms. Key figures include a 21% preferential visceral fat reduction, a weight-independent 20% MACE reduction, and 38 to 50% lower metastatic progression rates across four obesity-linked cancers. These numbers shift the risk-benefit calculus decisively toward net benefit for body-composition practitioners.

July 29, 2026 · 9 min read
Clinical Review Extrapolated

What Does the 2026 Springer Review Reveal About Tirzepatide's Cardio-Renal Integration Mechanisms and Their Metabolic Performance Implications?

The 2026 Springer review in Endocrine (doi:10.1007/s12020-026-04686-5) identifies tirzepatide's cardio-renal axis as a mechanistically distinct integration layer. Dual GIP/GLP-1 receptor co-agonism reduces left ventricular mass, lowers NT-proBNP, cuts composite cardiorenal events versus dulaglutide, and slows eGFR decline — outcomes that reframe tirzepatide's value for metabolically compromised performance users carrying cardiovascular risk.

July 27, 2026 · 9 min read
Metabolic Longevity Extrapolated

What Structural Features of Dietary Geroprotective Peptides Enable Nrf2, IIS, and mTOR Modulation for Metabolic Longevity in 2026?

Dietary geroprotective peptides modulate Nrf2, IIS, and mTOR through three converging structural rules: molecular weight below 1 kDa for intestinal permeation, hydrophobic or aromatic C-terminal residues for Keap1 displacement and receptor docking, and ETGE-like sequence motifs that mimic endogenous signaling ligands. These features are now mappable by AI-driven structure-activity pipelines, directly linking food-protein sequence to conserved longevity network outputs.

July 23, 2026 · 10 min read
Clinical Review Extrapolated

What Does the 2026 Systems Medicine View of Semaglutide Reveal About Its Inflammatory, Lipid, and ECM Pathways?

A 2026 review in Expert Review of Clinical Pharmacology (Tandfonline) applies a systems medicine framework to semaglutide, integrating proteomic and metabolomic datasets with major RCT outcomes. The synthesis identifies three converging pathway clusters — inflammatory signalling, lipid remodelling, and extracellular matrix regulation — that collectively explain why semaglutide's metabolic effects exceed what GLP-1 receptor agonism alone predicts.

July 22, 2026 · 10 min read
Metabolic Performance Extrapolated

How Does the Computationally Discovered BRP Peptide Compare to GLP-1 Agonists for Weight Loss Without Gastric Emptying Side Effects in 2026?

BRP (BRINP2-related peptide) is a computationally identified 12-amino-acid peptide that suppresses appetite and reduces fat mass in rodents and minipigs via a hypothalamic cAMP–PKA–CREB–FOS signaling axis entirely distinct from incretin pathways. Unlike GLP-1 receptor agonists, BRP produced no conditioned taste aversion or delayed gastric emptying in preclinical models, while generating a comparable or stronger hypothalamic Fos response than GLP-1 itself.

July 20, 2026 · 9 min read
Clinical Review Extrapolated

How Does Tirzepatide Function as a Multi-Organ Metabolic Integrator, and What Do 2026 Molecular Mechanisms Mean for Body Composition?

The 2026 Springer review establishes tirzepatide as a genuine multi-organ metabolic integrator: its dual GIP/GLP-1 receptor co-agonism simultaneously reshapes adipose lipolysis, hepatic lipid flux, skeletal muscle glucose uptake, and pancreatic beta-cell function. The net body composition result is 22 to 25 percent total weight loss with approximately 75 percent attributable to fat mass, outperforming semaglutide monotherapy in comparative analyses.

July 16, 2026 · 10 min read
75%
mean increase in IGF-1 levels with CJC-1295 at 12 weeks
— Teichman et al., 2006, JCEM

Browse by Category

All Articles Clinical Review Metabolic Metabolic Longevity Metabolic Oncology Metabolic Performance Metabolic Signalling Preclinical Regulatory

About Peptidegenics

Learn more →

Peptidegenics covers the intersection of peptide biochemistry, nutrition science, and metabolic physiology. Every article is grounded in published research. Nothing is sold here.

The Metabolic Applicability Rating on each article answers the question the performance-focused reader actually asks: does this evidence apply to how I actually eat and train, or is this a lab finding I cannot act on?

About this publication  ·  Editorial policy & the Metabolic Applicability Rating →